|Day's Range||1.0000 - 1.0000|
So far, Charlotte’s Web Holdings (CWBHF) (CWEB) has gained 19.7% year-to-date. The company will report its third-quarter results next month.
HEXO (HEXO) will report its fourth-quarter earnings before the market opens on Thursday. There has been a lot of pessimism surrounding the stock.
Aurora Cannabis (ACB) will report its earnings for the first quarter of fiscal 2020 next month. Reuters expects the company to report its earnings on November 11.
The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.
In the lightning round on Mad Money last week, Jim Cramer said that Canopy Growth needs a packaged goods CEO to make the stock price go up.
Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...
CALGARY , Oct. 21, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced over $797,000 in systemwide gross sales from the 26 branded Canna Cabana and KushBar retail cannabis stores from Thursday, October 17th – the first anniversary of the legalization of recreational cannabis for adult use across Canada (the "Anniversary of Legalization") – through Saturday, October 19, 2019 . Similar to its yearly reporting of retail sales related to April 20th , also known as '4/20' in cannabis culture, the Company expects to announce the results associated with the annual Anniversary of Legalization going forward.
On the markets front, Cronos Group Inc (NASDAQ: CRON) posted gains of up to 40% on Wednesday’s after-hours session. Aphria Inc (TSX: APHA) (NYSE: APHA) went on a rally after reporting net first-quarter revenue of CA$126.1 million ($95.3 million), up 849% year-over-year, on revenue for adult-use cannabis of CA$20million, up 8% quarter-over-quarter. The company posted positive adjusted EBITDA of CA$1 million and adjusted EBITDA from cannabis operations of CA$1.3 million in the quarter.
The vaping crisis has brought on some twists and turns for the cannabis sector. New York courts are now weighing an e-cigarette ban.
Tilray (NASDAQ:TLRY), like other cannabis equities, continues to suffer from the effects of the bursting stock bubble. Tilray stock traded as high as $300 per share during the run-up in marijuana stocks, which preceded Canadian legalization in 2018. Since then, it has lost more than 92% of its value. This includes a nearly 35% drop in less than a week following its August earnings report.Source: Shutterstock To be sure, declines have hammered marijuana stocks across the board. Also, once the dust settles, the company holds key assets and partnerships that could eventually take TLRY stock higher.However, Tilray stock needs both changing sentiment and a more discernible path to stability before it can stem its decline.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sector Selloff Hits TLRY StockTLRY trades at just over $22 per share. Despite this massive drop, TLRY stock still appears overvalued. Currently, it trades at about 24.3 times sales.In fairness, cannabis stocks have dropped across the board. Both Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) trade near 52-week lows. Moreover, companies such as Aphria (NYSE:APHA), which just beat earnings by 10 cents CAD per share, have also struggled. Many blame both changing sentiment against marijuana stocks as well as an oversupply of dried cannabis. * 7 Reasons to Buy Canopy Growth Stock In short, stocks that could do no wrong 18 months ago can now do no right. This bodes poorly for Tilray stock. InvestorPlace's Mark Hake even floated the possibility that TLRY could go bankrupt. Investors cannot write off that possibility as its reserves dwindle.TLRY holds about $180 million in cash. Since it lost $35 million in the last quarter, it can only maintain its current pace for so long. Moreover, Tilray cannot assume further debt will be an option. As of the previous quarterly report, the company held $430 million in long-term debt and $360 million in total equity. Hence, the financials indicate that the company may have to dilute its already beleaguered stock further when it comes time to seek more funding. TLRY Could Recover -- EventuallyDespite a bleak outlook and a lack of profits, investors still have reasons to keep watching Tilray stock. Much like the positive sentiment surrounding marijuana stocks did not last, investors should not assume the negative outlook will remain forever. When attitudes change, Wall Street may again pay attention to Tilray's attributes. Analysts forecast a 313.9% increase in revenue for this year. They also believe revenues will rise an additional 85.5% in fiscal 2020.Moreover, its partnerships and assets could eventually help TLRY. The company has partnered with a subsidiary of Novartis (NYSE:NVS) to distribute and sell branded medical cannabis products. It also entered into a joint venture with Anheuser-Busch InBev (NYSE:BUD) to research THC and CBD-infused beverages. Tilray also owns Manitoba Harvest, the world's largest hemp food manufacturer.This bodes well for continuing revenue growth. However, getting to the point where rising revenues can finally yield profits will probably lead to actions that place more strain on both the balance sheet and TLRY. Until the company can get to a place where it stops diluting Tilray stock, investors have little reason to buy. My Final Thoughts on Tilray StockTilray stock will struggle to move higher without improving its financials and without a more positive outlook from Wall Street on the cannabis sector. The bubble in TLRY continues to pop. The stock still appears pricey despite trading more than 90% below its all-time high. Sentiment has turned against marijuana stocks as losses continue and the industry contends with a glut in dried cannabis.Despite these obstacles, an eventual bullish scenario could develop for Tilray stock. It has built partnerships with established players in other industries. This could bode well for the Nanaimo, British Columbia-based firm as medicinal marijuana and cannabis-infused beverages find a market.However, for now, TLRY stock faces challenges as losses mount and liquid assets dwindle. Options for more funding will probably strain both the balance sheet and Tilray stock itself. For this reason, investors should probably brace for further near-term declines.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons to Buy Canopy Growth Stock * 7 Restaurant Stocks to Leave on Your Plate * 4 Turnaround Plays to Buy Now The post Investors Beware: Tilray Stock Might Not Be Done Dropping appeared first on InvestorPlace.
Despite vaping concerns, Aurora Cannabis plans to introduce vape products in December. Reports of vaping-related illnesses started in late August.
Aphria (APHA), Trulieve (TCNNF) and Organigram (OGI) have separated themselves from most of the cannabis pack, based upon managing to turn a profit.In the near term I believe these three companies should continue to do well, but in the longer term, they face challenges concerning profitability that some of their larger competitors decided to deal with in the early stages of growth.For that reason these companies are getting rewarded now, but that could change as the tide turns and they are forced to look for ways to grow both the top and bottom lines.In this article we'll look at what that challenge is and the potential impact on the long-term growth and potential profitability of the three companies.What the market is looking for nowWith the fear trade on in the broader market and investors starting to look for profits in the cannabis industry, those companies able to generate a profit at this time are being rewarded for their performance.I've mentioned for awhile now that the market was transitioning from a primary focus on growth and revenue to profits in the cannabis sector. That moment has obviously arrived from the way investors have been responding to those generating a profit, with the caveat of whether or not they'll be able to maintain that profit if they enter into serious expansion.But for the next three quarters or so, I see the market continuing to look for profits in the cannabis sector until questions start to arise concerning how the companies will grow their top lines.In other words, I see the market reversing direction, probably by the end of the first calendar 2020 quarter, and by latest, the second calendar quarter.The reason for that is because by that time, as far as Aphria and Organigram go, Canada will have at least a full quarter of two of derivative sales, which will give a clear picture as the potential upside for both the top and bottom lines.With sales likely to jump in Canada from derivative products and the increase in retail outlets, investors are going to want to see how the companies is going to grow revenue going forward.Trulieve (TCNNF)The challenge these companies face is they are positioning themselves as being able to generate a profit, when in reality the major reason for that is because of their more modest expansion goals in the near term.For example, Trulieve is the dominant player in Florida, but is now staring to look outside that market for growth. It will eventually be forced to spend a lot of money to gain market share in other markets, and they aren't likely to duplicate its performance in Florida because competitors already are taking a significant piece of the markets Trulieve will be competing in.Eventually this will put downward pressure on earnings, and the market will punish it under that scenario, unless it reports significant revenue growth at the time it starts to boost expenditures.OrganiGram (OGI) As for OrganiGram, the location of its base on the Atlantic coast has given it an edge on competitors for now, but after they are finished battling for market share in Quebec and Ontario, they will expand to the less populated parts of Canada. The company will face a lot more competition when that happens.Because of its unique growing process, OrganiGram is one of the market leaders in yield. According to the company, it produces about 230 grams per square foot, against the industry average of between 75 and 125 grams per square foot.With the goal of producing 113,000 kilograms annually, the upside potential of OrganiGram is limited, and I think it'll struggle to maintain market share once its larger competitors take aim at the primary market it competes in.Its yields are a competitive advantage now, but when its larger competitors, through much larger scale, cut back their price per gram as well, much of its current competitive advantage is going to evaporate.Aphria (APHA)Of these three companies, Aphria appears to have the best chance at sustainbly enjoying revenue and earnings growth over the long haul. Its production capacity will eventually climb to about 255,000 kilograms a year, which will only be behind a couple of its larger competitors.It also has a strong balance sheet of $464 million of cash and marketable securities, giving it a cushion in the current soft cannabis market.Looking ahead, it guides for revenue of C$650 million to C$700 million and adjusted Ebitda of C$88 million to C$95 million for fiscal 2020.As with the majority of its Canadian-based counterparts, it did miss on revenue in the latest quarter, although that is without a doubt the consequence of the slow rollout of retail outlets in Canada. That should vastly improve over the next several quarters.ConclusionIn the near term I think Aphria, Trulieve and Organigram should continue to do very well, as long as they continue to generate profits.Once investors start to look for future prospects for revenue growth, at that time I think these companies could start to receive downward pressure if they haven't shown the market how they're going to grow over the long term.Of these three, I think Organigram is the most susceptible to weakness, followed by Trulieve, because of its primary exposure to Florida, and the need to spend a lot more to keep up with fast-growing MSOs, who as with their larger Canadian peers, are taking their hits now rather than later.Aphria in my view has the best chance of these three to generate probable long-term sustainable growth on the top and bottom lines. I'm not convinced it'll be able to keep up with its larger competitors as they grow while slashing costs, but it has the potential to at least keep near the top in the Canadian market. How it competes internationally in the years ahead will probably dictate its ultimate success.For now though, all three of these companies should enjoy strength in their share prices as long as the market favors profitability over growth. Once that changes, they will face challenging times because of how larger competitors are boosting sales while turning a profit.To find good ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched feature that unites all of TipRanks’ equity insights.
Cronos Group (CRON) stock rose 33% with a heavy volume in after-hours trading on Wednesday. Marijuana stocks are on a rollercoaster ride.
Round two of the WeTrader Competition, hosted by the zero-commission online trading platform Webull, is quickly approaching its end at the closing bell of Friday’s session. The competition tasks traders to formulate their best paper trading strategy over the course of four weekly rounds for the chance to win an Amazon.com, Inc. (NASDAQ: AMZN). Winners from each round will also be eligible to compete in the Championship Round for a grand prize of either a $40,000 student loan payment or a Tesla Inc. (NASDAQ: TSLA) Model 3 .
On Wednesday, Aurora Cannabis gave a preview of its Cannabis 2.0 strategy. The company provided plans for the roll-out of edibles, concentrates, and vapes.
Aphria Inc. stock fell 8% Wednesday to pace decliners in the cannabis sector, a day after it reported earnings for its fiscal first quarter that showed a profit that was mostly due to a change in its stock price and shift in its stake in another company.
In 2007, New Mexico was the 12th state to legalize medical cannabis in the US. However, the state hasn't legalized marijuana for recreational use.
Aphria (APHA) reported impressive results for the first quarter of fiscal 2020 on Tuesday. The stock has gained 9.6% since its earnings.
Oct. 17 marks one full year of legalized cannabis in Canada — and the road to this moment could have been smoother. “Canada’s rollout of legalization has been hampered by a number of things,” Alan Brochstein, author of 420 Investor, said this week on Benzinga’s PreMarket Prep show. “They should have opened up medical dispensaries first and gotten that distribution out there,” Brochstein said.
CALGARY , Oct. 17, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, today announced that the KushBar retail store located in Unit #7 at 8807 100th Street in Morinville (the "KushBar Store") received its first delivery of cannabis products from Alberta Gaming, Liquor and Cannabis ("AGLC") and today will begin selling recreational cannabis products and accessories. To celebrate the grand opening of this location, festivities will take place at the KushBar Store on Saturday, October 19th .
Noah Hamman, CEO of AdvisorShares, tells Yahoo Finance's Alexis Christoforous and Brian Sozzi why he's still bullish on cannabis stocks.